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clinical characteristics and 
outcomes of methamphetamine-
associated versus non-
methamphetamine intracerebral 
hemorrhage
Zhu Zhu1,2, Sahar osman1, Dana Stradling1, Mohammad Shafie1 & Wengui Yu  1*
Methamphetamine use has emerged as a risk factor for intracerebral hemorrhage (ICH). We aim to 
investigate the clinical characteristics and outcomes of methamphetamine-associated ICH (Meth-ICH) 
versus Non-Meth-ICH. Patients with ICH between January 2011 and December 2017 were studied. 
Meth-ICH and Non-Meth-ICH were defined by history of abuse and urine drug screen (UDS). The clinical 
features of the 2 groups were explored. Among the 677 consecutive patients, 61 (9.0%) were identified 
as Meth-ICH and 350 as Non-Meth ICH. Meth-ICH was more common in Hispanics (14.6%) and Whites 
(10.1%) as compared to Asians (1.2%). Patients with Meth-ICH were more often younger (51.2 vs. 62.2 
years, p < 0.001), male (77.0% vs. 61.4.0%, p < 0.05), and smokers (44.3% vs. 13.4%, p < 0.001). Non-
Meth-ICH was more likely to have history of hypertension (72.61% v. 59%, p < 0.05) or antithrombotic 
use (10.9% vs. 1.6%, p < 0.05). There was no significant difference in clinical severity, hospital length of 
stay (LOS), rate of functional independence (29.5% vs. 25.7%, p = 0.534), or mortality (18.0% vs. 24.6%, 
p = 0.267) between the 2 groups. Methamphetamine use was not an independent predictor of poor 
outcome. Despite difference in demographics, Meth-ICH is similar to Non-Meth ICH in hospital course 
and outcome.
Spontaneous intracerebral hemorrhage (ICH) is a devastating type of strokes1,2. The reported median 30-day 
mortality ranges from 17% to 40%, with rates of functional independency between 12% and 39%1. Recent ran-
domized controlled studies have shown no significant benefit from intensive blood pressure control and early 
surgical intervention3–5. Since spontaneous ICH is potentially preventable, it is therefore a research priority to 
investigate any emerging risk of the disease.
Methamphetamine use is a serious public health crisis, with estimated 37 million active users and 2.6 mil-
lion disability-adjusted life years lost in 20106,7. Caplan at al. initially described incidence of intracerebral and 
subarachnoid hemorrhage from methamphetamine abuse8,9. Ischemic stroke was subsequently reported to be 
associated with methamphetamine use as well10–14.
Both population-based study and forensic analysis of fatal strokes showed significant predominance of hemor-
rhagic strokes in young methamphetamine users15,16. Methamphetamine use was associated with approximately 
fivefold increase in hemorrhagic stroke, twice higher than the risk from either cocaine or tobacco15. Lappin et al. 
performed a systemic review of methamphetamine-related stroke in 2017 and identified 81 hemorrhagic and 17 
ischemic stroke cases from case reports and single center series17. Both types of stroke were approximately twice 
as common in males.
There appears to be an alarming trend of increasing prevalence of methamphetamine-associated ICH 
(Meth-ICH) in the regions around the Pacific rim17. Ho et al. initially described 11 patients with Meth-ICH 
at University of California San Francisco Medical Center between 2003 and 200713. Nakagawa et al. then iden-
tified 25 patients with Meth-ICH (13%) at Queen’s Medical Center in Hawaii between July 2011 and January 
201418. Most recently, Swor et al. reported 41 Meth-ICH (16.4%) at University of California Davis Medical Center 
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between January 2013 and December 201619. Although Meth-ICH was increasingly reported in younger adults, 
there were conflicting data on hospital course and outcome17–20.
As the only academic Comprehensive Stroke Center in Orange County, California, we have witnessed signif-
icant increase in ICH volume in the last 5 years. The objective of this study was to investigate the demographics, 
hospital course, and outcome of Meth-ICH in comparison to Non-Meth-ICH.
Methods
This is a retrospective observational study. It was approved by the University of California Irvine Institutional 
Review Board (IRB) and the Ethics Committee. Informed consents were waived as part of the IRB approval. All 
methods in the study were performed in accordance with the relevant guidelines and regulations.
Consecutive patients with spontaneous ICH at the University of California Irvine Comprehensive Stroke 
Center between January 1, 2011 and December 31, 2017 were identified by searching electronic medical records 
and the prospectively maintained American Heart Association (AHA)-Get With The Guidelines (GWTG)-Stroke 
Registry. ICH from cerebral aneurysm, arteriovenous malformation, brain tumors, coagulopathy, or trauma were 
excluded. Patients with Meth-ICH were identified by recorded history of methamphetamine use or a positive 
urine drug screen (UDS) at the time of admission. The UDS was performed using EMIT II Plus Amphetamines 
assay (1,000 ng/mL cutoff) with a sensitivity and specificity of 94.3% and 93.3%, respectively21. Those with a pos-
itive UDS while taking trazodone, Adderall, bupropion, or labetalol within 2 weeks of admission were excluded 
due to potential false-positive result22. Patients with no history of methamphetamine use and a negative UDS were 
included in Non-Meth-ICH group. Patients who denied history of drug abuse but had no UDS were excluded 
from the comparison analysis. All ICH patients were initially managed in the dedicated Neuroscience ICU with 
standard ICH order-set and clinical pathway by board-certified neurointensivists.
The following information was abstracted from chart review and the AHA GWTG-Stroke Registry: age, gender, 
race, past medical history, the highest blood pressure (BP) levels within 24 hours of admission, baseline National 
Institutes of Health Stroke Scale (NIHSS) score, Glasgow Coma Scale (GCS) score in ED, home medications, ICH 
location, intraventricular hemorrhage (IVH), ICH score, laboratory and imaging results, surgical interventions, 
ventilator support, length of stay (LOS) in the intensive care unit (ICU) and hospital, and modified Rankin Scale 
(mRS) at hospital discharge.
ICH location was categorized into deep (basal ganglia or thalamus), lobar, brainstem, cerebellum, multifocal 
or primary IVH23. ICH score was calculated as previously described24. Functional outcome was estimated per 
mRS. Since patients with mRS 3–5 could improve within 3–6 months after ICH, functional independence (mRS 
0–2) and mortality (mRS 6) at hospital discharge were used as endpoints to explore the factors associated with 
outcomes.
Statistical analysis. Continuous variables were described by mean ± standard deviation (SD) or median 
with interquartile range (IQR) based on the results of normality testing. Categorical variables were expressed by 
counts with percentages. Baseline characteristics and outcomes at discharge were compared between Meth-ICH 
and Non-Meth-ICH groups by Wilcoxon rank-sum test for continuous variables and χ2 test for categorical 
variables. Univariate analyses were performed initially to assess the possible factors associated with outcomes 
(functional independence and mortality at discharge). The cutoff value in univariate analysis for inclusion in 
the multivariate logistic regression was p < 0.1. Analyses were performed using SPSS software (version 23.0). A 
2-tailed value of p < 0.05 was considered statistically significant.
Results
Demographics of patients with Meth-ICH and Non-Meth-ICH. A total of 677 consecutive patients 
with spontaneous ICH between January 1, 2011 and December 31, 2017 were included. The flow chart for identi-
fication of Meth-ICH and Non-Meth-ICH is shown in Fig. 1. Thirty-two patients had recorded history of meth-
amphetamine use. Among them, 30 had a UDS and 21 (70%) tested positive, indicative of methamphetamine use 
within the last 3 days21. Of the 645 patients who denied history of methamphetamine use, 379 (58.8%) had a UDS 
and 29 of them (7.7%) tested positive for amphetamine. Therefore, a total of 61 patients in the entire cohort (9%) 
were identified to have Meth-ICH (highlighted in pink color in Fig. 1). Given the fact that 7.7% of the patients 
who denied history of methamphetamine use had a positive UDS, the rate of Meth-ICH could be higher if all 
patients had a UDS.
As highlighted in blue color in Fig. 1, the 350 patients who denied a history of methamphetamine use and also 
had a negative UDS were classified as Non-Meth-ICH.
The mean age of the cohort was 63.4 ± 15.9 (range 18–100). Three hundred ninety-eight patients (58.8%) were 
male. There were 286 White (42.2%), 192 Hispanic (28.4%), 166 Asian (24.5%), and 33 African-American (4.9%) 
patients (Fig. 2). The rate of Meth-ICH was significantly higher in Hispanics (14.6% vs 1.2%; OR = 14.29, 95% 
CI 2.70–50.00; p < 0.001) and Whites (10.1% vs 1.2%; OR = 9.09, 95% CI 2.17–33.33; p < 0.001) than in Asians.
The characteristics of the patients with Meth-ICH or Non-Meth-ICH are summarized in Table 1. Compared 
with Non-Meth-ICH group, the patients with Meth-ICH were significantly younger (51.2 + 7.5 vs 62.2 + 15.9; 
p < 0.001) and more likely to be male (77% vs 61.4%; p = 0.019) and smokers (44.3% vs 13.4%, p < 0.001). 
Non-Meth-ICH was more likely to have history of hypertension (72.61% v. 59%, p < 0.05) or antithrombotic use 
(10.9% vs. 1.6%, p < 0.05). There was no significant difference in highest systolic blood pressure (SBP) or diastolic 
blood pressure (DBP) within 24 hours of admission, NIHSS, GCS or ICH score between the 2 groups.
There was significant difference in ICH location between the 2 groups (p = 0.001), with Meth-ICH group hav-
ing less lobar hemorrhage (OR = 0.32, 95%CI 0.16–0.65, p = 0.001) and more primary IVH (OR = 6.16, 95%CI 
1.73–21.97, p = 0.009).
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Although Meth-ICH was more often treated with surgical interventions, likely due to younger ages, there 
was no significant difference in requirement for ventilator support and LOS in the ICU or hospital between the 
2 groups.
There was also no significant difference in either functional independence (OR = 1.21, 95% CI 0.66–2.20; 
p = 0.534) or mortality rate at hospital discharge (OR = 0.68, 95% CI 0.34–1.36; p = 0.267). Methamphetamine 
use per se was not a predictor of poor outcomes in patients with ICH.
Predictors of outcomes. Factors associated with functional independency and mortality at hospital dis-
charge were analyzed using univariate and multivariate models. Overall, lower NIHSS and higher GCS score were 
associated with functional independence at hospital discharge per multivariate analysis (Table 2). Higher NIHSS, 
ICH score, ventilator support, and absence of surgical interventions were independent predictors of mortality 
(Table 3).
Discussion
This study represents the largest single center cohort of Meth-ICH yet reported. It demonstrates that metham-
phetamine is an important risk factor for ICH in young males, smokers, Hispanic and White populations in 
Southern California. The rate of Meth-ICH was 9% in our large cohort, as compared to 13% and 16.4% reported 
previously18,19. Of note, of the 645 patients who denied history of methamphetamine use, only 379 patients 
(58.8%) had a UDS and 29 (7.7%) were urine positive for amphetamine. The actual rate of Meth-ICH could be 
significantly higher if all ICH patients had a UDS.
The observed age disparities in patients with Meth-ICH versus Non-Meth-ICH were consistent with previous 
reports18,19.
Although ordering UDS at admission was routine practice at our Stroke Center, the decision to obtain the test 
was at the discretion of the ED and on-call stroke team. Previous report showed ethnic disparities in ordering 
drug screens in patient with ICH, with young African Americans having more UDS25. We examined the ordering 
Figure 1. Flow chart for patient selection. Meth-ICH: reported a history methamphetamine use or had a 
positive urine drug screen (marked in pink); Non-Meth-ICH: denied a history of methamphetamine use and 
had a negative urine drug screen (marked in blue).
Figure 2. Racial disparities in the prevalence of Meth-ICH.
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of drug screens for ICH patients between 2013 and 201726. Of the 596 ICH patients, 357 (60%) had a UDS. A UDS 
was more likely to be obtained in patients who were younger (age < 45), male, smokers, self-reported metham-
phetamine users, with more severe deficit at presentation (NIHSS > 4), without diabetes, or not taking anticoag-
ulant. There was no significant difference in UDS among different races (p = 0.319)26. Therefore, the higher rates 
of Meth-ICH in Hispanics and Whites were not due to bias in ordering UDS. In addition, hypertensive ICH is 
very prevalent in Asians2. However, only 1.2% (2/166) Asians in this cohort had Meth-ICH. These findings may 
have significant public health implication and may guide targeted community education for the prevention of 
Meth-ICH.
The majority of Meth-ICH was located in the basal ganglia/thalamus, suggesting deep white matter 
small-vessel injuries from direct toxicity of methamphetamine or increased sympathetic system activation15,17,27. 
The proportion of lobar hemorrhage was significantly higher in Non-Meth-ICH (38.0% vs 16.4%), likely due to 
older age and history of hypertension, ischemic stroke, or cerebral amyloid angiopathy28–30.
In our current study, there was no significant difference in ICH severity, ventilator support, LOS in the 
ICU or hospital, rate of functional independence or mortality at hospital discharge between Meth-ICH and 
Variables
Meth-ICH 
(n = 61)
Non-Meth-ICH 
(n = 350) p
Age 51.2 ± 7.5 62.2 ± 15.9 <0.001
Male 47 (77.0) 215 (61.4) 0.019
Past medical history
 Hypertension 36 (59.0) 254 (72.6) 0.032
 Diabetes 9 (14.8) 83 (23.7) 0.121
 Hyperlipidemia 7 (11.5) 70 (20.0) 0.115
 Cardiac diseases 3 (4.9) 37 (10.6) 0.169
 Antithrombotic agents 1 (1.6) 38 (10.9) 0.023
 Smoking 27 (44.3) 47 (13.4) <0.001
SBP, mmHga 180.9 ± 41.5 181.2 ± 40.6 0.711
DBP, mmHga 102.5 ± 24.1 99.5 ± 23.9 0.678
NIHSS 19 (6, 27) 12 (2, 22) 0.065
GCS 10 (4,16) 14 (10, 18) 0.084
ICH location 0.001
  Deep 35 (57.4) 163 (46.6) 0.119
  Lobar 10 (16.4) 133 (38.0) 0.001
  Brainstem 8 (13.1) 26 (7.4) 0.137
  Cerebellum 3 (4.9) 22 (6.3) 0.783
  Primary IVH 5 (8.2) 5 (1.4) 0.009
  Multifocal 0 (0) 1 (0.3) 1.000
IVH 35 (57.4) 167 (47.7) 0.164
ICH score 0.911
  0 16 (26.2) 94 (26.9)
  1 15 (24.6) 93 (26.6)
  2 9 (14.8) 49 (14.0)
  3 11 (18.0) 51 (14.6)
  4 9 (14.8) 45 (12.9)
  5 1 (1.6) 16 (4.6)
  6 0 (0) 2 (0.6)
Ventilator support 28 (45.9) 157 (45.0) 0.894
Surgical intervention 27 (44.3) 103 (29.4) 0.022
ICU LOS (days) 6 ± 6 7 ± 6 0.903
Hospital LOS (days) 14 ± 14 11 ± 10 0.056
mRS at discharge 0.328
mRS 0–2 18 (29.5) 90 (25.7) 0.534
mRS 3–4 23 (37.7) 102 (29.2)
mRS 5 9 (14.8) 72 (20.6)
mRS 6 (Death) 11 (18.0) 86 (24.6) 0.267
Table 1. Characteristics of patients with Meth-ICH or Non-Meth-ICH. Abbreviations: SBP, systolic blood 
pressure; DBP, diastolic blood pressure;. NIHSS, National Institutes of Health Stroke Scale; GCS, Glasgow Coma 
Scale;. ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage;. ICU, Intensive Care Unit; mRS, 
modified Rankin Scale; LOS, length of stay. aHighest SBP/DBP within 24 hours of admission. Data are n (%), 
mean ± SD, or median (interquartile range, IQR).
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Non-Meth-ICH. The severity of neurologic deficits at admission was the main predictor of functional independ-
ence and mortality. Methamphetamine use and demographic features including age were not independently asso-
ciated with outcomes as they had been in previous studies17,29,30.
Of note, our findings are significantly different from what was previously reported. Swor et al. showed that 
patients with Meth-ICH had significantly longer LOS in the ICU (10 ± 8 vs 5 ± 5 days) and hospital (18 ± 27 vs 
8 ± 8 days) than Non-Meth-ICH19. They also showed higher mortality rates (29% vs 34%), as compared to our 
study (18% vs 25%). Several factors may account for lack of difference in LOS between the two groups and lower 
mortality rates in our study. First, although the Meth-ICH patients had higher NIHSS score, they were younger 
with less comorbidities as compared with Non-Meth-ICH patients. Second, there was no significant difference in 
highest blood pressures, GCS, ICH score and ventilator support between Meth-ICH and Non-Meth-ICH groups. 
Third, all ICH patients were initially managed in the dedicated Neuroscience ICU with standard ICH order-set 
and clinical pathway by board-certified neurointensivits at our center. Management of ICH by neurocritical care 
specialists have been shown to be associated with shorter LOS and reduced mortality31–33.
The mechanisms by which methamphetamine may cause ICH remains unclear. In 1970, Citron et al. studied 
14 patients with polysubstance abuse, with almost all admitting methamphetamine use, and found necrotizing 
angiitis in medium-sized and small arteries of the brain and other organs34. Rumbaugh et al. analyzed the angio-
graphic features of patients with methamphetamine abuse and described beaded arteries, segmental changes in 
vessel caliber, and regions of slow flow35. In monkeys receiving intravenous methamphetamine for two weeks, 
angiography showed similar beading and segmental changes, and necropsy revealed small cerebral hemorrhages, 
zones of infarction, and microaneurysms36. Davis et al. reported 4.9% incidence of methamphetamine intoxi-
cation in all autopsies in San Diego County from 1 January 1987 to 31 December 1993 and suggested possible 
propagation and rupture of berry aneurysms from methamphetamine use37. Of note, methamphetamine is a 
potent sympathomimetic. ICH may also occur secondary to methamphetamine-induced hypertensive surge in 
the absence of pre-existing cerebrovascular disease38. Chronic use of methamphetamine may cause long-term 
systemic hypertension and vessel damage13,17,27,39. Further studies are warranted to investigate the mechanisms 
of Meth-ICH.
To the best of our knowledge, this is the largest single-center cohort to compare the clinical characteristics and 
outcomes of patients with Meth-ICH versus Non-Meth-ICH. Our study demonstrates that there is no significant 
difference in severity of ICH, LOS, favorable outcome and mortality between Meth-ICH and Non-Meth-ICH. 
In addition, we found considerable proportion of patients who denied history of methamphetamine use turned 
out to have positive urine drug test, indicating possible higher prevalence of methamphetamine use in patients 
with ICH. The strengths of this study are the comprehensive comparison of the clinical features and outcomes 
of Meth-ICH verse non-Meth-ICH. Our findings provide better understanding of Meth-ICH vs Non-Meth-ICH 
and may help develop strategies for the effective treatment and prevention of Meth-ICH.
Our study has a few limitations. First, this is a single-center study performed in Southern California. Our 
findings may not be generalizable to other regions or populations. Second, despite denying drug use history and 
negative urine drug test, it is still possible that there were undetected meth users in the Non-Meth-ICH group. 
Variables
Functional independence (n = 108)
Univariate 
analysis
Multivariate 
analysis
pp OR (95% CI)
Age 0.486
Male 0.462
Race 0.304
HTN 0.076 0.54 (0.28–1.05) 0.07
DM 0.164
Smoking 0.002 1.35 (0.67–2.71) 0.405
Antithrombotic agents 0.390
Meth use 0.534
ICH location 0.394
SBP 0.515
DBP 0.257
NIHSS  < 0.001 0.73 (0.67–0.80) <0.001
GCS  < 0.001 1.29 (1.07–1.56) 0.008
ICH score <0.001 0.89 (0.56–1.30) 0.454
Glucose 0.332
Creatinine 0.583
Surgical interventions <0.001 0.88 (0.29–2.68) 0.821
Ventilator support <0.001 0.41 (0.13–1.29) 0.128
Table 2. Factors associated with functional independence at discharge. Abbreviations: SBP, systolic blood 
pressure; DBP, diastolic blood pressure; NIHSS. National Institutes of Health Stroke Scale; GCS, Glasgow Coma 
Scale. ICH, intracerebral hemorrhage; mRS, modified Rankin Scale.
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The relatively small sample size in the Meth-ICH group and possible undetected meth users in the Non-Meth 
ICH group may contribute to the lack of difference in hospital course and mortality between the two groups. 
Studies with large sample size will be needed in the future to validate our findings. Third, in this retrospective 
study, there was no information about the route (inhalation, ingestion or injection), frequency, and duration of 
methamphetamine use in most patients. The temporal relationship between recent methamphetamine use and 
ICH onset could not be established. In addition, UDS is only sensitive in detecting amphetamines within 4 days of 
recent use and may not identify chronic users. Lastly, patients may have history of polysubstance abuse. Of note, 
cocaine and excessive alcohol use are also risk factor for ICH40,41. Cocaine was only detected in 2 of the 50 patients 
with UDS-confirmed methamphetamine use and could not be significant compounding factor in our cohort. 
However, we had no data on excessive alcohol use in our case series.
In summary, methamphetamine use is an emerging risk factor for ICH in young males, smokers, Hispanic 
and White populations in Southern California. There is no significant difference in ICH severity, LOS in the ICU 
or hospital, functional independence or mortality rate between Meth-ICH and Non-Meth-ICH. Targeted public 
and community education may be essential for the prevention of Meth-ICH.
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